Cargando…

Azithromycin Mass Treatment for Trachoma Control: Risk Factors for Non-Participation of Children in Two Treatment Rounds

BACKGROUND: Persistent non-participation of children in mass drug administration (MDAs) for trachoma may reduce program impact. Risk factors that identify families where participation is a problem or program characteristics that foster non-participation are poorly understood. We examined risk factor...

Descripción completa

Detalles Bibliográficos
Autores principales: Ssemanda, Elizabeth N., Levens, Joshua, Mkocha, Harran, Munoz, Beatriz, West, Sheila K.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2012
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3308937/
https://www.ncbi.nlm.nih.gov/pubmed/22448296
http://dx.doi.org/10.1371/journal.pntd.0001576
_version_ 1782227457798045696
author Ssemanda, Elizabeth N.
Levens, Joshua
Mkocha, Harran
Munoz, Beatriz
West, Sheila K.
author_facet Ssemanda, Elizabeth N.
Levens, Joshua
Mkocha, Harran
Munoz, Beatriz
West, Sheila K.
author_sort Ssemanda, Elizabeth N.
collection PubMed
description BACKGROUND: Persistent non-participation of children in mass drug administration (MDAs) for trachoma may reduce program impact. Risk factors that identify families where participation is a problem or program characteristics that foster non-participation are poorly understood. We examined risk factors for households with at least one child who did not participate in two MDAs compared to households where all children participated in both MDAs. METHODS/PRINCIPAL FINDINGS: We conducted a case control study in 28 Tanzanian communities. Cases included all 152 households with at least one child who did not participate in the 2008 and 2009 MDAs with azithromycin. Controls consisted of a random sample of 460 households where all children participated in both MDAs. A questionnaire was asked of all families. Random-intercept logistic regression models were used to estimate odds ratios (ORs) and 95% confidence intervals (CIs), control for clustering, and adjust for community size. In total, 140 case households and 452 control households were included in the analyses. Compared to controls, guardians in case households had higher odds of reporting excellent health (OR 4.12 (CI 95% 1.57–10.86)), reporting a burden due to family health (OR 3.15 (95% CI 1.35–7.35)), reduced ability to rely on others for assistance (OR 1.66 (95% CI 1.01–2.75)), being in a two (versus five) days distribution program (OR 3.31 (95% CI 1.68–6.50)) and living in a community with <2 community treatment assistants (CTAs)/1000 residents (OR 2.07 (95% CI 1.04–4.12). Furthermore, case households were more likely to have more children, younger guardians, unfamiliarity with CTAs, and CTAs with more travel time to their assigned households (p-values<0.05). CONCLUSIONS/SIGNIFICANCE: Compared to full participation households, households with persistent non-participation had a higher burden of familial responsibility and seemed less connected in the community. Additional distribution days and lessening CTAs' travel time to their furthest assigned households may prevent non-participation.
format Online
Article
Text
id pubmed-3308937
institution National Center for Biotechnology Information
language English
publishDate 2012
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-33089372012-03-23 Azithromycin Mass Treatment for Trachoma Control: Risk Factors for Non-Participation of Children in Two Treatment Rounds Ssemanda, Elizabeth N. Levens, Joshua Mkocha, Harran Munoz, Beatriz West, Sheila K. PLoS Negl Trop Dis Research Article BACKGROUND: Persistent non-participation of children in mass drug administration (MDAs) for trachoma may reduce program impact. Risk factors that identify families where participation is a problem or program characteristics that foster non-participation are poorly understood. We examined risk factors for households with at least one child who did not participate in two MDAs compared to households where all children participated in both MDAs. METHODS/PRINCIPAL FINDINGS: We conducted a case control study in 28 Tanzanian communities. Cases included all 152 households with at least one child who did not participate in the 2008 and 2009 MDAs with azithromycin. Controls consisted of a random sample of 460 households where all children participated in both MDAs. A questionnaire was asked of all families. Random-intercept logistic regression models were used to estimate odds ratios (ORs) and 95% confidence intervals (CIs), control for clustering, and adjust for community size. In total, 140 case households and 452 control households were included in the analyses. Compared to controls, guardians in case households had higher odds of reporting excellent health (OR 4.12 (CI 95% 1.57–10.86)), reporting a burden due to family health (OR 3.15 (95% CI 1.35–7.35)), reduced ability to rely on others for assistance (OR 1.66 (95% CI 1.01–2.75)), being in a two (versus five) days distribution program (OR 3.31 (95% CI 1.68–6.50)) and living in a community with <2 community treatment assistants (CTAs)/1000 residents (OR 2.07 (95% CI 1.04–4.12). Furthermore, case households were more likely to have more children, younger guardians, unfamiliarity with CTAs, and CTAs with more travel time to their assigned households (p-values<0.05). CONCLUSIONS/SIGNIFICANCE: Compared to full participation households, households with persistent non-participation had a higher burden of familial responsibility and seemed less connected in the community. Additional distribution days and lessening CTAs' travel time to their furthest assigned households may prevent non-participation. Public Library of Science 2012-03-20 /pmc/articles/PMC3308937/ /pubmed/22448296 http://dx.doi.org/10.1371/journal.pntd.0001576 Text en Ssemanda et al. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited.
spellingShingle Research Article
Ssemanda, Elizabeth N.
Levens, Joshua
Mkocha, Harran
Munoz, Beatriz
West, Sheila K.
Azithromycin Mass Treatment for Trachoma Control: Risk Factors for Non-Participation of Children in Two Treatment Rounds
title Azithromycin Mass Treatment for Trachoma Control: Risk Factors for Non-Participation of Children in Two Treatment Rounds
title_full Azithromycin Mass Treatment for Trachoma Control: Risk Factors for Non-Participation of Children in Two Treatment Rounds
title_fullStr Azithromycin Mass Treatment for Trachoma Control: Risk Factors for Non-Participation of Children in Two Treatment Rounds
title_full_unstemmed Azithromycin Mass Treatment for Trachoma Control: Risk Factors for Non-Participation of Children in Two Treatment Rounds
title_short Azithromycin Mass Treatment for Trachoma Control: Risk Factors for Non-Participation of Children in Two Treatment Rounds
title_sort azithromycin mass treatment for trachoma control: risk factors for non-participation of children in two treatment rounds
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3308937/
https://www.ncbi.nlm.nih.gov/pubmed/22448296
http://dx.doi.org/10.1371/journal.pntd.0001576
work_keys_str_mv AT ssemandaelizabethn azithromycinmasstreatmentfortrachomacontrolriskfactorsfornonparticipationofchildrenintwotreatmentrounds
AT levensjoshua azithromycinmasstreatmentfortrachomacontrolriskfactorsfornonparticipationofchildrenintwotreatmentrounds
AT mkochaharran azithromycinmasstreatmentfortrachomacontrolriskfactorsfornonparticipationofchildrenintwotreatmentrounds
AT munozbeatriz azithromycinmasstreatmentfortrachomacontrolriskfactorsfornonparticipationofchildrenintwotreatmentrounds
AT westsheilak azithromycinmasstreatmentfortrachomacontrolriskfactorsfornonparticipationofchildrenintwotreatmentrounds